Trials / Unknown
UnknownNCT03084952
Phase 2 Trial to Evaluate 18-Methoxycoronaridine Efficacy, Safety and Tolerability in Cutaneous Leishmaniasis Patients
A Phase 2, Randomized, Unicentric Clinical Trial With Dose Scaling for Safety, Tolerability and Efficacy Assessment of 18-Methoxycoronaridine Administered to Cutaneous Leishmaniasis Patients
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 52 (estimated)
- Sponsor
- Infan Industria Quimica Farmaceutica Nacional · Industry
- Sex
- All
- Age
- 18 Years – 59 Years
- Healthy volunteers
- Not accepted
Summary
It is a randomized phase II clinical study, unicentre aimed to evaluate the tolerability, safety and efficacy of 18-Methoxyoronaridine as a candidate of tegumentary leishmaniasis treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 18-Methoxycoronaridine | Drug under evaluation for leishmaniasis treatment |
| DRUG | Glucantime | Leishmaniasis standard drug in Brazil |
Timeline
- Start date
- 2021-05-01
- Primary completion
- 2023-12-01
- Completion
- 2024-07-01
- First posted
- 2017-03-21
- Last updated
- 2020-03-19
Source: ClinicalTrials.gov record NCT03084952. Inclusion in this directory is not an endorsement.